Associated Disease Details
| Disease ID: | I08 |
| DO ID: | 114 |
| Disease Name: | Cardiovascular system disease |
| Definition: | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system |
| Synonyms: | Atrial Fibrillation; Angina Pectoris; heart disease; Myocardial Infarction; Chronic heart failure |
| Class: | disease of anatomical entity |
| Related Drugs: | Digoxin; Atorvastatin; Ranolazine; Aspirin; Epanova; Spironolactone |
| Mechanism: | Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiological mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these 2 diseases offers the opportunity to further develop targeted therapies. |
| Reference (PMIDs): | 30819364 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D008 | Alpha-tocopherol | Chemical drug | DB00163 | NR1I2; ALOX5; DGKA | -- | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D058 | Canagliflozin | Chemical drug | DB08907 | SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D084 | Coenzyme Q10 | Chemical drug | DB09270 | -- | -- | Under clinical trials | Details |
| D085 | Colesevelam | Chemical drug | DB00930 | -- | Anticholesteremic drug | Under clinical trials | Details |
| D112 | Digoxin | Chemical drug | DB00390 | ATP1A1 inhibitor; ATP1A2 inhibitor; ATP1A3 inhibitor; ATP1A4 inhibitor | Antiarrhythmic | Under clinical trials | Details |
| D115 | DS102 | Miscellany | -- | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0008 | DB00022 | approved | biotech | Peginterferon alfa-2b | Therapeutic strategy associated | Details |
| R0030 | DB00107 | approved; vet_approved | biotech | Oxytocin | Indication associated | Details |
| R0035 | DB00119 | approved; investigational; nutraceutical | small molecule | Pyruvic acid | Indication associated | Details |
| R0038 | DB00125 | investigational; nutraceutical | small molecule | Arginine | Therapeutic strategy associated | Details |
| R0043 | DB00132 | approved; investigational; nutraceutical | small molecule | alpha-Linolenic acid | Therapeutic strategy associated | Details |
| R0055 | DB00157 | approved; nutraceutical | small molecule | NADH | Target associated | Details |
| R0056 | DB00159 | approved; nutraceutical | small molecule | Icosapent | Therapeutic strategy associated | Details |
| R0057 | DB00169 | approved; nutraceutical | small molecule | Cholecalciferol | Therapeutic strategy associated | Details |
| R0062 | DB00175 | approved | small molecule | Pravastatin | Target associated | Details |
| R0063 | DB00176 | approved; investigational | small molecule | Fluvoxamine | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00005 | 35258483 | Endocr Connect | Menopause-associated risk of cardiovascular disease. | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | Details |
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | Details |
| A00013 | 35255263 | Lancet Oncol | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | Details |
| A00070 | 35232007 | Clin Mol Hepatol | NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals. | Details |
| A00086 | 35225189 | Br J Nutr | Organ meat consumption and risk of nonalcoholic fatty liver disease: the TCLSIH study. | Details |
| A00088 | 35223941 | Front Nutr | Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. | Details |
| A00099 | 35220605 | Hepatology | Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. | Details |
| A00107 | 35217817 | Acta Pharmacol Sin | Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. | Details |
| A00112 | 35216556 | BMC Endocr Disord | Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | Details |
| A00117 | 35215517 | Nutrients | Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases. | Details |
| A00126 | 35212997 | Methods Mol Biol | Metabolic Phenotyping in Mice with NASH Using Indirect Calorimetry. | Details |
| A00149 | 35208241 | Metabolites | Assessment of Exposure to Di-(2-ethylhexyl) Phthalate (DEHP) Metabolites and Bisphenol A (BPA) and Its Importance for the Prevention of Cardiometabolic Diseases. | Details |
| A00153 | 35207239 | J Clin Med | Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. | Details |
| A00157 | 35204710 | Biomolecules | Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. | Details |
| A00168 | 35203457 | Biomedicines | Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. | Details |
| A00173 | 35199429 | HIV Med | "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". | Details |
| A00176 | 35197660 | Acta Inform Med | Biochemical Parameters as Predictors of Underlying Liver Disease in Patients with Chronic Kidney Disorders. | Details |